Immune checkpoint inhibitors for first-line treatment of advanced non-small-cell lung cancer: A systematic review and network meta-analysis.
Sign Up to like & getrecommendations! Published in 2021 at "Thoracic cancer"
DOI: 10.1111/1759-7714.14148
Abstract: OBJECTIVE Currently, several immune checkpoint inhibitors (ICIs) treatment for advanced non-small-cell lung cancer (NSCLC) have been investigated; their overall efficacy and safety remain unclear. METHODS We searched electronic databases such as PubMed, EMBASE, and the… read more here.
Keywords: chemotherapy; platinum based; pembrolizumab plus; plus platinum ... See more keywords
Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study
Sign Up to like & getrecommendations! Published in 2022 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.14328
Abstract: This study analyzed the efficacy and safety of neoadjuvant chemotherapy with liposomal paclitaxel plus platinum in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC). read more here.
Keywords: locally advanced; plus platinum; neoadjuvant chemotherapy; paclitaxel plus ... See more keywords
Effect of renin-angiotensin system inhibitors on pemetrexed plus platinum-induced hematological toxicities: a multicenter retrospective study using three propensity score analyses.
Sign Up to like & getrecommendations! Published in 2021 at "Die Pharmazie"
DOI: 10.1691/ph.2021.1409
Abstract: Hematological toxicities induced by pemetrexed plus platinum therapy remain a critical issue in clinical practice. We hypothesized that inhibition of the renin-angiotensin system (RAS) can ameliorate pemetrexed-induced hematological toxicities through drug-drug interactions involving organic anion… read more here.
Keywords: hematological toxicities; renin angiotensin; plus platinum; pemetrexed plus ... See more keywords
Comparing the cost-effectiveness of sintilimab + pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2023 at "Translational Cancer Research"
DOI: 10.21037/tcr-22-2030
Abstract: Background Pemetrexed plus platinum alone is the conventional first-line therapy for locally advanced metastatic nonsquamous non-small cell lung cancer (NSCLC) without targetable genetic aberrations. The ORIENT-11 trial revealed that sintilimab + pemetrexed plus platinum could… read more here.
Keywords: plus platinum; patients nonsquamous; cost; first line ... See more keywords
Efficacy Analysis of Adjuvant Chemotherapy with Gemcitabine Plus Platinum or S-1 in Biliary Tract Carcinoma: A Multi-Center Retrospective Study
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Management and Research"
DOI: 10.2147/cmar.s290083
Abstract: Purpose Biliary tract cancers (BTCs) have a poor overall prognosis, as patients who underwent curative surgery frequently experience disease recurrence. At present, there is a paucity of well-documented adjuvant chemotherapy regimen. This study aimed to… read more here.
Keywords: chemotherapy; biliary tract; plus platinum; gemcitabine plus ... See more keywords
Pretreatment Fibrinogen-Albumin Ratio (FAR) Associated with Treatment Response and Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Anti-PD-1 Therapy Plus Platinum-Based Combination Chemotherapy
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Management and Research"
DOI: 10.2147/cmar.s347547
Abstract: Purpose PD-1 inhibitors have been routinely used to treat advanced non-small cell lung cancer (NSCLC) and have significantly improved clinical outcomes. In this study, we aimed to explore the influence of pretreatment fibrinogen-albumin ratio (FAR)… read more here.
Keywords: plus platinum; anti therapy; survival; first line ... See more keywords
First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2020.602185
Abstract: Background The aim of the present study was to evaluate the cost-effectiveness of durvalumab plus platinum–etoposide versus platinum–etoposide as first-line treatments for small-cell lung cancer from the perspective of the US payer. Methods This study… read more here.
Keywords: plus platinum; cost; durvalumab plus; platinum etoposide ... See more keywords
Efficacy, safety, and prognostic factors of apatinib plus platinum doublet chemotherapy in advanced non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cancer Research and Therapeutics"
DOI: 10.4103/jcrt.jcrt_1853_21
Abstract: Background: Anti-angiogenesis drugs are applicable in treating advanced non-small cell lung cancer (NSCLC); however, the related data regarding apatinib, a Chinese domestic anti-vascular endothelial growth factor receptor-2 (VEGFR-2) production, are limited. Therefore, this study explored… read more here.
Keywords: apatinib plus; plus platinum; doublet chemotherapy; platinum doublet ... See more keywords